Pfizer Inc. has signed a collaboration agreement with Karo Bio AB, of Stockholm, Sweden, for the development of small-molecule modulators of retinoic acid-related orphan receptor (ROR-gamma), an enticing newer target with relevance for autoimmune disease.
ROR-gamma controls production and secretion of cytokine IL-17. Recent clinical studies using monoclonal antibodies to neutralize IL-17 have validated the pathway's significance for inflammation, heating up the race for a ROR-gamma drug.
"It's a tough race, with tough competition," said Karo Bio CEO Per Bengtsson. "We have Pfizer. They have stakes in this field, and strong ambitions."
Under the agreement, Karo Bio may receive up to $217 …
No comments:
Post a Comment